PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16330466-11	2006	CONCLUSIONS: The dual blockade of RAS with low-dose ramipril plus candesartan was found to be safe and offered additive benefits with respect to reducing proteinuria and urinary TGF-beta1 excretion in diabetic patients with advanced kidney disease.	candesartan	66-77	transforming growth factor beta 1	Homo sapiens	178-187	
16178483-6	2005	We also examined the effects of the angiotensin-converting enzyme inhibitor (ACEI) perindoprilat and the AII receptor blocker (ARB) candesartan on expression of TGF-beta1 and proliferation of HPMC.	candesartan	132-143	transforming growth factor beta 1	Homo sapiens	161-170	
25473119-7	2015	The amount of TGF-beta1 was increased in the culture medium of angiotensin II-treated cells, and this effect was inhibited by candesartan or PD123319.	candesartan	126-137	transforming growth factor beta 1	Homo sapiens	14-23	
25224569-4	2014	Candesartan significantly reduced TGF-beta1 expression and epithelial-to-mesenchymal transition-like change, while tumor proliferation and stromal fibrosis were impaired.	candesartan	0-11	transforming growth factor beta 1	Homo sapiens	34-43